Nanotechnology approaches for ocular drug delivery

Middle East African Journal of Ophthalmology

Volumn 20, Issue 1, 2013, Pages 26-37

  Xu, Qingguo ^a   Kambhampati, Siva P ^a,b   Kannan, Rangaramanujam M ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Wayne State University   (United States)

Author keywords

Age Related Macular Degeneration; Dendrimers; Nanoparticles; Ocular Gene Therapy; Targeted Therapies

Indexed keywords

ACICLOVIR; CARBOMER; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CYCLOSPORIN A; DENDRIMER; DEXAMETHASONE; ERYTHROMYCIN; EUDRAGIT; EYE DROPS; FLUOCINOLONE ACETONIDE; MAGNETIC NANOPARTICLE; MUCIN; MULTIDRUG RESISTANCE PROTEIN; NANOPARTICLE; POLYAMIDOAMINE; POLYGLACTIN; PREDNISOLONE; PROTEIN FLT23K; SMALL INTERFERING RNA; TG 0054; TIMOLOL; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN INHIBITOR;

ANTERIOR EYE SEGMENT; BLOOD RETINA BARRIER; CONFERENCE PAPER; CORNEA DISEASE; CORNEA DRYNESS; CORNEA INJURY; CORNEA NEOVASCULARIZATION; CORNEA TRANSPLANTATION; CORNEAL RESIDENCE TIME; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELUTING CONTACT LENS; DRUG FORMULATION; DRUG PENETRATION; DRUG RETENTION; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG UPTAKE; DRY EYE; EYE DISEASE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HYDROGEL; MOLECULAR IMPRINTING; NANOENCAPSULATION; NANOMEDICINE; NANOTECHNOLOGY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; OPEN ANGLE GLAUCOMA; PARTICLE SIZE; POSTERIOR EYE SEGMENT; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA EDEMA; RETINITIS PIGMENTOSA; RISK BENEFIT ANALYSIS; RNA INTERFERENCE; SINGLE DRUG DOSE; SUBRETINAL NEOVASCULARIZATION; SUSTAINED RELEASE PREPARATION; SYSTEMIC DISEASE; UVEITIS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VISUAL SYSTEM PARAMETERS;

AGE-RELATED MACULAR DEGENERATION; DENDRIMERS; NANOPARTICLES; OCULAR GENE THERAPY; TARGETED THERAPIES;

DRUG DELIVERY SYSTEMS; EYE DISEASES; GENETIC THERAPY; HUMANS; MOLECULAR TARGETED THERAPY; NANOMEDICINE; NANOTECHNOLOGY;

EID: 84878785223     PISSN: 09749233     EISSN: 09751599     Source Type: Journal    
DOI: 10.4103/0974-9233.106384     Document Type: Conference Paper

References (99)

1. Tabbara KF, Ross-Degnan D. Blindness in Saudi Arabia. JAMA 1986;255:3378-84.
2. Al-Shamsi HN, Dueker DK, Nowilaty SR, Al-Shahwan SA. Neovascular glaucoma at king khaled eye specialist hospital - etiologic considerations. Middle East Afr J Ophthalmol 2009;16:15-9.
3. KACST. Strategic Priorities for Advanced Medical and Health Research, 2-46. Available from: http://www.kacst.edu.sa/en/ research/Documents/ MedicalAndHealth.pdf. [Last accessed on 2012 Dec 18].
4. KACST. Strategic Priorities for Nanotechnology Program, 2-62. Available from: http://www.kacst.edu.sa/en/research/ Documents/Nanotechnology.pdf. [Last accessed on 2012 Dec 18].
5. Duncan R, Gaspar R. Nanomedicine(s) under the microscope. Mol Pharm 2011;8:2101-41.
6. Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano 2009;3:16-20.
7. Shi J, Votruba AR, Farokhzad OC, Langer R. Nanotechnology in drug delivery and tissue engineering: From discovery to applications. Nano Lett 2010;10:3223-30.
8. Goldberg M, Langer R, Jia X. Nanostructured materials for applications in drug delivery and tissue engineering. J Biomater Sci Polym Ed 2007;18:241-68.
9. Meisner D, Mezei M. Liposome ocular delivery systems. Adv Drug Deliv Rev 1995;16:75-93.
10. Samad A, Sultana Y, Aqil M. Liposomal drug delivery systems: An update review. Curr Drug Deliv 2007;4:297-305.
11. Kaur IP, Garg A, Singla AK, Aggarwal D. Vesicular systems in ocular drug delivery: An overview. Int J Pharm 2004;269:1-14.
12. Ebrahim S, Peyman GA, Lee PJ. Applications of liposomes in ophthalmology. Surv Ophthalmol 2005;50:167-82.
13. Bochot A, Fattal E. Liposomes for intravitreal drug delivery: A state of the art. J Control Release 2012;161:628-34.
14. Smolin G, Okumoto M, Feiler S, Condon D. Idoxuridineliposome therapy for herpes simplex keratitis. Am J Ophthalmol 1981;91:220-5.
15. Dharma SK, Fishman PH, Peyman GA. A preliminary study of corneal penetration of 125I-labelled idoxuridine liposome. Acta Ophthalmol (Copenh) 1986;64:298-301.
16. Zimmer A, Kreuter J. Microspheres and nanoparticles used in ocular delivery systems. Adv Drug Deliv Rev 1995;16:61-73.
17. Nagarwal RC, Kant S, Singh PN, Maiti P, Pandit JK. Polymeric nanoparticulate system: A potential approach for ocular drug delivery. J Control Release 2009;136:2-13.
18. Cheng Y, Xu Z, Ma M, Xu T. Dendrimers as drug carriers: Applications in different routes of drug administration. J Pharm Sci 2008;97:123-43.
19. Agrawal AK, Das M, Jain S. In situ gel systems as 'smart' carriers for sustained ocular drug delivery. Expert Opin Drug Deliv 2012;9:383-402.
20. Gratieri T, Gelfuso GM, Lopez RFV, Souto EB. Current efforts and the potential of nanomedicine in treating fungal keratitis. Expert Rev Ophthalmol 2010;5:365-84.
21. Ludwig A. The use of mucoadhesive polymers in ocular drug delivery. Adv Drug Deliv Rev 2005;57:1595-639.
22. Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. AAPS J 2010;12:348-60.
23. Gipson IK, Argüeso P. Role of mucins in the function of the corneal and conjunctival epithelia. Int Rev Cytol 2003;231: 1-49.
24. Aksungur P, Demirbilek M, Denkbaş EB, Vandervoort J, Ludwig A, Unlü N. Development and characterization of Cyclosporine A loaded nanoparticles for ocular drug delivery: Cellular toxicity, uptake, and kinetic studies. J Control Release 2011;151:286-94.
25. Bravo-Osuna I, Noiray M, Briand E, Woodward AM, Argüeso P, Molina Martínez IT, et al. Interfacial interaction between transmembrane ocular mucins and adhesive polymers and dendrimers analyzed by surface plasmon resonance. Pharm Res 2012;29:2329-40.
26. Zambito Y, Di Colo G. Thiolated quaternary ammonium-chitosan conjugates for enhanced precorneal retention, transcorneal permeation and intraocular absorption of dexamethasone. Eur J Pharm Biopharm 2010;75:194-9.
27. du Toit LC, Pillay V, Choonara YE, Govender T, Carmichael T. Ocular drug delivery - a look towards nanobioadhesives. Expert Opin Drug Deliv 2011;8:71-94.
28. Mitra AK. Role of transporters in ocular drug delivery system. Pharm Res 2009;26:1192-6.
29. Hariharan S, Gunda S, Mishra GP, Pal D, Mitra AK. Enhanced corneal absorption of erythromycin by modulating P-glycoprotein and MRP mediated efflux with corticosteroids. Pharm Res 2009;26:1270-82.
30. Majumdar S, Hingorani T, Srirangam R, Gadepalli RS, Rimoldi JM, Repka MA. Transcorneal permeation of L- and D-aspartate ester prodrugs of acyclovir: Delineation of passive diffusion versus transporter involvement. Pharm Res 2009;26:1261-9.
31. Katragadda S, Gunda S, Hariharan S, Mitra AK. Ocular pharmacokinetics of acyclovir amino acid ester prodrugs in the anterior chamber: Evaluation of their utility in treating ocular HSV infections. Int J Pharm 2008;359:15-24.
32. Giannavola C, Bucolo C, Maltese A, Paolino D, Vandelli MA, Puglisi G, et al. Influence of preparation conditions on acyclovir-loaded poly-d,l-lactic acid nanospheres and effect of PEG coating on ocular drug bioavailability. Pharm Res 2003;20:584-90.
33. Jwala J, Boddu SH, Shah S, Sirimulla S, Pal D, Mitra AK. Ocular sustained release nanoparticles containing stereoisomeric dipeptide prodrugs of acyclovir. J Ocul Pharmacol Ther 2011;27:163-72.
34. Jung HJ, Chauhan A. Temperature sensitive contact lenses for triggered ophthalmic drug delivery. Biomaterials 2012;33:2289-300.
35. Kapoor Y, Thomas JC, Tan G, John VT, Chauhan A. Surfactantladen soft contact lenses for extended delivery of ophthalmic drugs. Biomaterials 2009;30:867-78.
36. Peng CC, Burke MT, Carbia BE, Plummer C, Chauhan A. Extended drug delivery by contact lenses for glaucoma therapy. J Control Release 2012;162:152-8.
37. Peng CC, Chauhan A. Extended cyclosporine delivery by silicone-hydrogel contact lenses. J Control Release 2011;154:267-74.
38. Ali M, Horikawa S, Venkatesh S, Saha J, Hong JW, Byrne ME. Zero-order therapeutic release from imprinted hydrogel contact lenses within in vitro physiological ocular tear flow. J Control Release 2007;124:154-62.
39. Ali M, Byrne ME. Controlled release of high molecular weight hyaluronic acid from molecularly imprinted hydrogel contact lenses. Pharm Res 2009;26:714-26.
40. White CJ, McBride MK, Pate KM, Tieppo A, Byrne ME. Extended release of high molecular weight hydroxypropyl methylcellulose from molecularly imprinted, extended wear silicone hydrogel contact lenses. Biomaterials 2011;32:5698-705.
41. White CJ, Byrne ME. Molecularly imprinted therapeutic contact lenses. Expert Opin Drug Deliv 2010;7:765-80.
42. Mintzer MA, Dane EL, O'Toole GA, Grinstaff MW. Exploiting dendrimer multivalency to combat emerging and re-emerging infectious diseases. Mol Pharm 2012;9:342-54.
43. Wang B, Navath RS, Menjoge AR, Balakrishnan B, Bellair R, Dai H, et al. Inhibition of bacterial growth and intramniotic infection in a guinea pig model of chorioamnionitis using PAMAM dendrimers. Int J Pharm 2010;395:298-308.
44. Navath RS, Menjoge AR, Dai H, Romero R, Kannan S, Kannan RM. Injectable PAMAM dendrimer-PEG hydrogels for the treatment of genital infections: Formulation and in vitro and in vivo evaluation. Mol Pharm 2011;8:1209-23.
45. Sosa AB, Epstein SP, Asbell PA. Evaluation of toxicity of commercial ophthalmic fluoroquinolone antibiotics as assessed on immortalized corneal and conjunctival epithelial cells. Cornea 2008;27:930-4.
46. Cheng Y, Qu H, Ma M, Xu Z, Xu P, Fang Y, et al. Polyamidoamine (PAMAM) dendrimers as biocompatible carriers of quinolone antimicrobials: An in vitro study. Eur J Med Chem 2007;42:1032-8.
47. Miki D, Dastgheib K, Kim T, Pfister-Serres A, Smeds KA, Inoue M, et al. A photopolymerized sealant for corneal lacerations. Cornea 2002;21:393-9.
48. Smeds KA, Pfister-Serres A, Miki D, Dastgheib K, Inoue M, Hatchell DL, et al. Photocrosslinkable polysaccharides for in situ hydrogel formation. J Biomed Mater Res 2001;54:115-21.
49. Wathier M, Jung PJ, Carnahan MA, Kim T, Grinstaff MW. Dendritic macromers as in situ polymerizing biomaterials for securing cataract incisions. J Am Chem Soc 2004;126:12744-5.
50. Grinstaff MW. Designing hydrogel adhesives for corneal wound repair. Biomaterials 2007;28:5205-14.
51. Degoricija L, Johnson CS, Wathier M, Kim T, Grinstaff MW. Photo cross-linkable biodendrimers as ophthalmic adhesives for central lacerations and penetrating keratoplasties. Invest Ophthalmol Vis Sci 2007;48:2037-42.
52. Berdahl JP, Johnson CS, Proia AD, Grinstaff MW, Kim T. Comparison of sutures and dendritic polymer adhesives for corneal laceration repair in an in vivo chicken model. Arch Ophthalmol 2009;127:442-7.
53. Klausner EA, Peer D, Chapman RL, Multack RF, Andurkar SV. Corneal gene therapy. J Control Release 2007;124:107-33.
54. Mohan RR, Tovey JC, Sharma A, Tandon A. Gene therapy in the cornea: 2005 - Present. Prog Retin Eye Res 2012;31:43-64.
55. Williams KA, Coster DJ. Gene therapy for diseases of the cornea - a review. Clin Experiment Ophthalmol 2010;38:93-103.
56. Qazi Y, Stagg B, Singh N, Singh S, Zhang X, Luo L, et al. Nanoparticle-mediated delivery of shRNA.VEGF-A plasmids regresses corneal neovascularization. Invest Ophthalmol Vis Sci 2012;53:2837-44.
57. Cho YK, Uehara H, Young JR, Tyagi P, Kompella UB, Zhang X, et al. Flt23k nanoparticles offer additive benefit in graft survival and anti-angiogenic effects when combined with triamcinolone. Invest Ophthalmol Vis Sci 2012;53:2328-36.
58. Hughes PM, Olejnik O, Chang-Lin JE, Wilson CG. Topical and systemic drug delivery to the posterior segments. Adv Drug Deliv Rev 2005;57:2010-32.
59. Duvvuri S, Majumdar S, Mitra AK. Drug delivery to the retina: Challenges and opportunities. Expert Opin Biol Ther 2003;3:45-56.
60. Hosoya K, Tachikawa M. Inner blood-retinal barrier transporters: Role of retinal drug delivery. Pharm Res 2009;26:2055-65.
61. Hosoya K, Tomi M, Tachikawa M. Strategies for therapy of retinal diseases using systemic drug delivery: Relevance of transporters at the blood-retinal barrier. Expert Opin Drug Deliv 2011;8:1571-87.
62. Edelhauser HF, Rowe-Rendleman CL, Robinson MR, Dawson DG, Chader GJ, Grossniklaus HE, et al. Ophthalmic drug delivery systems for the treatment of retinal diseases: Basic research to clinical applications. Invest Ophthalmol Vis Sci 2010;51: 5403-20.
63. Sakurai E, Ozeki H, Kunou N, Ogura Y. Effect of particle size of polymeric nanospheres on intravitreal kinetics. Ophthalmic Res 2001;33:31-6.
64. Kim JH, Kim JH, Kim KW, Kim MH, Yu YS. Intravenously administered gold nanoparticles pass through the blood-retinal barrier depending on the particle size, and induce no retinal toxicity. Nanotechnology 2009;20:505101.
65. Amrite AC, Edelhauser HF, Singh SR, Kompella UB. Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration. Mol Vis 2008;14:150-60.
66. Amrite AC, Kompella UB. Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration. J Pharm Pharmacol 2005;57:1555-63.
67. Kim H, Robinson SB, Csaky KG. Investigating the movement of intravitreal human serum albumin nanoparticles in the vitreous and retina. Pharm Res 2009;26:329-37.
68. Koo H, Moon H, Han H, Na JH, Huh MS, Park JH, et al. The movement of self-assembled amphiphilic polymeric nanoparticles in the vitreous and retina after intravitreal injection. Biomaterials 2012;33:3485-93.
69. Peeters L, Sanders NN, Braeckmans K, Boussery K, Van de Voorde J, De Smedt SC, et al. Vitreous: A barrier to nonviral ocular gene therapy. Invest Ophthalmol Vis Sci 2005;46:3553-61.
70. Sanders NN, Peeters L, Lentacker I, Demeester J, De Smedt SC. Wanted and unwanted properties of surface PEGylated nucleic acid nanoparticles in ocular gene transfer. J Control Release 2007;122:226-35.
71. Roy S, Zhang K, Roth T, Vinogradov S, Kao RS, Kabanov A. Reduction of fibronectin expression by intravitreal administration of antisense oligonucleotides. Nat Biotechnol 1999;17:476-9.
72. Kadam RS, Tyagi P, Edelhauser HF, Kompella UB. Influence of choroidal neovascularization and biodegradable polymeric particle size on transscleral sustained delivery of triamcinolone acetonide. Int J Pharm 2012;434:140-7.
73. Thakur A, Kadam RS, Kompella UB. Influence of drug solubility and lipophilicity on transscleral retinal delivery of six corticosteroids. Drug Metab Dispos 2011;39:771-81.
74. Misra GP, Singh RS, Aleman TS, Jacobson SG, Gardner TW, Lowe TL. Subconjunctivally implantable hydrogels with degradable and thermoresponsive properties for sustained release of insulin to the retina. Biomaterials 2009;30:6541-7.
75. Bourges JL, Gautier SE, Delie F, Bejjani RA, Jeanny JC, Gurny R, et al. Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest Ophthalmol Vis Sci 2003;44:3562-9.
76. Shelke NB, Kadam R, Tyagi P, Rao VR, Kompella UB. Intravitreal Poly(L-lactide) Microparticles Sustain Retinal and Choroidal Delivery of TG-0054, a Hydrophilic Drug Intended for Neovascular Diseases. Drug Deliv Transl Res 2011;1:76-90.
77. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007;114:2179-82.
78. Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005;46:726-33.
79. Gupta SK, Velpandian T, Dhingra N, Jaiswal J. Intravitreal pharmacokinetics of plain and liposome-entrapped fluconazole in rabbit eyes. J Ocul Pharmacol Ther 2000;16:511-8.
80. Robinson R, Viviano SR, Criscione JM, Williams CA, Jun L, Tsai JC, et al. Nanospheres delivering the EGFR TKI AG1478 promote optic nerve regeneration: The role of size for intraocular drug delivery. ACS Nano 2011;5:4392-400.
81. Kannan R, Iezzi R, Kannan S, Guru B, inventors; Dendrimercontaining particles for sustained release of compounds. patent application US 2011/0034422 A1; Regular patents filed in US (#12/681,516), Canada (#2,701,291), European Union (#08835693.6), Japan (#2010e528216) and India (1247/ ELNP/2010). 02/10/2011.
82. Iezzi R, Guru BR, Glybina IV, Mishra MK, Kennedy A, Kannan RM. Dendrimer-based targeted intravitreal therapy for sustained attenuation of neuroinflammation in retinal degeneration. Biomaterials 2012;33:979-88.
83. Kannan S, Dai H, Navath RS, Balakrishnan B, Jyoti A, Janisse J, et al. Dendrimer-based postnatal therapy for neuroinflammation and cerebral palsy in a rabbit model. Sci Transl Med 2012;4:130ra46.
84. Conley SM, Naash MI. Nanoparticles for retinal gene therapy. Prog Retin Eye Res 2010;29:376-97.
85. Cai X, Conley SM, Nash Z, Fliesler SJ, Cooper MJ, Naash MI. Gene delivery to mitotic and postmitotic photoreceptors via compacted DNA nanoparticles results in improved phenotype in a mouse model of retinitis pigmentosa. FASEB J 2010;24:1178-91.
86. Cai X, Nash Z, Conley SM, Fliesler SJ, Cooper MJ, Naash MI. A partial structural and functional rescue of a retinitis pigmentosa model with compacted DNA nanoparticles. PLoS One 2009;4:e5290.
87. Ding XQ, Quiambao AB, Fitzgerald JB, Cooper MJ, Conley SM, Naash MI. Ocular delivery of compacted DNA-nanoparticles does not elicit toxicity in the mouse retina. PLoS One 2009;4:e7410.
88. Boylan NJ, Suk JS, Lai SK, Jelinek R, Boyle MP, Cooper MJ, et al. Highly compacted DNA nanoparticles with low MW PEG coatings: In vitro, ex vivo and in vivo evaluation. J Control Release 2012;157:72-9.
89. Koirala A, Makkia RS, Cooper MJ, Naash MI. Nanoparticlemediated gene transfer specific to retinal pigment epithelial cells. Biomaterials 2011;32:9483-93.
90. Campbell M, Humphries P. Size-selective and in vitro assessment of inner blood retina barrier permeability. Methods Mol Biol 2011;763:355-67.
91. Campbell M, Ozaki E, Humphries P. Systemic delivery of therapeutics to neuronal tissues: A barrier modulation approach. Expert Opin Drug Deliv 2010;7:859-69.
92. Campbell M, Nguyen AT, Kiang AS, Tam LC, Gobbo OL, Kerskens C, et al. An experimental platform for systemic drug delivery to the retina. Proc Natl Acad Sci U S A 2009;106:17817-22.
93. Singh SR, Grossniklaus HE, Kang SJ, Edelhauser HF, Ambati BK, Kompella UB. Intravenous transferrin, RGD peptide and dualtargeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV. Gene Ther 2009;16:645-59.
94. Prow TW, Bhutto I, Kim SY, Grebe R, Merges C, McLeod DS, et al. Ocular nanoparticle toxicity and transfection of the retina and retinal pigment epithelium. Nanomedicine 2008;4:340-9.
95. Raju HB, Hu Y, Vedula A, Dubovy SR, Goldberg JL. Evaluation of magnetic micro- and nanoparticle toxicity to ocular tissues. PLoS One 2011;6:e17452.
96. Marano RJ, Toth I, Wimmer N, Brankov M, Rakoczy PE. Dendrimer delivery of an anti-VEGF oligonucleotide into the eye: A long-term study into inhibition of laser-induced CNV, distribution, uptake and toxicity. Gene Ther 2005;12:1544-50.
97. Zhang K, Zhang L, Weinreb RN. Ophthalmic drug discovery: Novel targets and mechanisms for retinal diseases and glaucoma. Nat Rev Drug Discov 2012;11:541-59.
98. Shapiro A, Lazar E. The renaissance of drug delivery systems for the posterior segment. Retina Today 2011:22-5.
99. Blindness FF. First gene therapy clinical trial for recessive RP is underway. 2011; Available from: http://www.blindness.org/ [Last accessed on 2012 Dec 18].